Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Quest PharmaTech Inc.

Market Cap 5.07M 3.58M 3.13M 2.9M 2.7M 339M 5.11M 34.41M 13.39M 166M 13.45M 13.16M 578M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 6.06M 4.28M 3.74M 3.46M 3.23M 404M 6.1M 41.09M 15.99M 199M 16.06M 15.72M 691M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
1 day-14.29%
1 week-14.29%
6 months-25.00%
Current year-14.29%
1 week 0.03
Extreme 0.03
0.04
1 month 0.03
Extreme 0.03
0.04
Current year 0.02
Extreme 0.025
0.04
1 year 0.02
Extreme 0.025
0.05
3 years 0.02
Extreme 0.015
0.1
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 16/06/2004
Director of Finance/CFO - 31/12/2004
Director TitleAgeSince
Director/Board Member - 16/06/2004
Chairman - 04/07/2021
Director/Board Member - 04/07/2021
Date Insider Type Main position Quantity % Market Cap.
12-11OtherCompany 0 0%
20/10/25Other

Chief Executive Officer

700,000 0.4139%
20/10/25Other

Chief Executive Officer

300,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
-14.29%-14.29%-40.00%-57.14% 4.18M
+0.34%+1.09%-10.67%-5.05% 43.13B
+1.73%+3.59%+318.08%+564.04% 34.65B
+0.61%+1.34%+10.00%+46.20% 30.03B
+0.02%-5.93%+8.45%-21.44% 28B
-1.06%-3.71%+9.08%+19.56% 24.45B
-1.23%+2.11% - - 14.34B
-0.99%-2.53%+47.29%+102.88% 13.14B
+1.54%+0.16%+6.69%+8.89% 12.53B
+2.39%+2.61%+102.86%+84.20% 12.25B
Average -1.09%-0.18%+50.20%+82.46% 21.25B
Weighted average by Cap. +0.40%-0.10%+67.03%+116.48%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.27M -1.11M -1.03M -959K -120M -1.81M -12.21M -4.75M -59.09M -4.77M -4.67M -205M 5M 3.53M 3.08M 2.85M 2.66M 334M 5.03M 33.9M 13.19M 164M 13.25M 12.96M 570M
Net Debt 795K 561K 490K 454K 423K 53.04M 801K 5.39M 2.1M 26.08M 2.11M 2.06M 90.6M 986K 696K 608K 563K 525K 65.77M 993K 6.68M 2.6M 32.34M 2.61M 2.56M 112M
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
22/06/26 0.0300 $ -14.29% 8,728
18/06/26 0.0350 $ -12.50% 68,669
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!